The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
The prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effect of bDMARDs and iJAK inhibitors on the condition...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2022-05-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687907329114112 |
|---|---|
| author | A. E. Karateev E. Yu. Polishchuk A. S. Potapova E. V. Matyanova A. S. Semashko А. O. Bobkova E. S. Filatova V. N. Amirjanova S. I. Glukhova E. G. Zotkin A. M. Lila |
| author_facet | A. E. Karateev E. Yu. Polishchuk A. S. Potapova E. V. Matyanova A. S. Semashko А. O. Bobkova E. S. Filatova V. N. Amirjanova S. I. Glukhova E. G. Zotkin A. M. Lila |
| author_sort | A. E. Karateev |
| collection | DOAJ |
| description | The prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effect of bDMARDs and iJAK inhibitors on the condition of patients with rheumatoid arthritis (RA), taking the patients reported outcomes, as well as the incidence of COVID-19 in these patients.Materials and methods. A telephone survey was conducted of 254 patients with RA (average age – 49.8±13.7 years; 64.4% of patients are positive for rheumatoid factor; women – 83.5%; DAS28 score – 5.4±1.6 points), who in the period from January 2020 to June 2021 were prescribed bDMARDs or iJAK for the first time: 148 (58.3%) – rituximab; 57 (22.4%) – tumor necrosis factor α inhibitors; 20 (7.9%) – iJAK; 17 (6.7%) – interleukin 6 inhibitors; 12 (4.7%) – abatacept.Results. At the time of the survey, 204 (80.3%) patients continued taking prescribed medications. The main reason for the interruption of treatment was administrative problems. Synthetic DMARDs (mainly methotrexate and leflunomide) were received by 68.0%, glucocorticoids – 45.3%, nonsteroidal anti-inflammatory drugs – 44.5% of respondents. Among patients treated with bDMARDs or iJAK, 68.1% noted «the state of symptoms acceptable to the patient», the absence of frequent joint pain – 65.3%, the absence of increased fatigue – 14.3%. The incidence of COVID-19 and hospitalization associated with this disease did not differ in individuals who continued and stopped using bDMARDs or iJAK: 41.2% and 44.6%, 13.7% and 14.0%, respectively (p=0.80884). There were no statistically significant differences in the incidence of COVID-19 and hospitalization associated with this disease in patients taking various bDMARDs or iJAK.Conclusion. Despite the COVID-19 pandemic, rituximab remains one of the most popular bDMARDs. About a third of patients receiving bDMARDs or iJAK are not satisfied with their condition. More than 40% of patients who received these drugs suffered COVID-19; 14.0% required hospitalization. |
| format | Article |
| id | doaj-art-dc6a09e7a01c413fb5ef3e047fee5693 |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2022-05-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-dc6a09e7a01c413fb5ef3e047fee56932025-08-20T03:22:12ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922022-05-0160214915610.47360/1995-4484-2022-149-1562790The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patientsA. E. Karateev0E. Yu. Polishchuk1A. S. Potapova2E. V. Matyanova3A. S. Semashko4А. O. Bobkova5E. S. Filatova6V. N. Amirjanova7S. I. Glukhova8E. G. Zotkin9A. M. Lila10V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian FederationThe prescribing of biological disease-modifying antirheumatic drugs (bDMARDs) and Janus kinase inhibitors (iJAK) during the COVID-19 pandemic requires a balanced approach and tight monitoring of the patients.The aim of the study was to study the effect of bDMARDs and iJAK inhibitors on the condition of patients with rheumatoid arthritis (RA), taking the patients reported outcomes, as well as the incidence of COVID-19 in these patients.Materials and methods. A telephone survey was conducted of 254 patients with RA (average age – 49.8±13.7 years; 64.4% of patients are positive for rheumatoid factor; women – 83.5%; DAS28 score – 5.4±1.6 points), who in the period from January 2020 to June 2021 were prescribed bDMARDs or iJAK for the first time: 148 (58.3%) – rituximab; 57 (22.4%) – tumor necrosis factor α inhibitors; 20 (7.9%) – iJAK; 17 (6.7%) – interleukin 6 inhibitors; 12 (4.7%) – abatacept.Results. At the time of the survey, 204 (80.3%) patients continued taking prescribed medications. The main reason for the interruption of treatment was administrative problems. Synthetic DMARDs (mainly methotrexate and leflunomide) were received by 68.0%, glucocorticoids – 45.3%, nonsteroidal anti-inflammatory drugs – 44.5% of respondents. Among patients treated with bDMARDs or iJAK, 68.1% noted «the state of symptoms acceptable to the patient», the absence of frequent joint pain – 65.3%, the absence of increased fatigue – 14.3%. The incidence of COVID-19 and hospitalization associated with this disease did not differ in individuals who continued and stopped using bDMARDs or iJAK: 41.2% and 44.6%, 13.7% and 14.0%, respectively (p=0.80884). There were no statistically significant differences in the incidence of COVID-19 and hospitalization associated with this disease in patients taking various bDMARDs or iJAK.Conclusion. Despite the COVID-19 pandemic, rituximab remains one of the most popular bDMARDs. About a third of patients receiving bDMARDs or iJAK are not satisfied with their condition. More than 40% of patients who received these drugs suffered COVID-19; 14.0% required hospitalization.https://rsp.mediar-press.net/rsp/article/view/3146rheumatoid arthritisbiological disease-modifying antirheumatic drugsjak inhibitorscovid-19 |
| spellingShingle | A. E. Karateev E. Yu. Polishchuk A. S. Potapova E. V. Matyanova A. S. Semashko А. O. Bobkova E. S. Filatova V. N. Amirjanova S. I. Glukhova E. G. Zotkin A. M. Lila The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients Научно-практическая ревматология rheumatoid arthritis biological disease-modifying antirheumatic drugs jak inhibitors covid-19 |
| title | The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
| title_full | The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
| title_fullStr | The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
| title_full_unstemmed | The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
| title_short | The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients |
| title_sort | use of biological disease modifying antirheumatic drugs and janus kinase inhibitors in rheumatoid arthritis during the covid 19 coronavirus disease pandemic data from a telephone survey of 254 patients |
| topic | rheumatoid arthritis biological disease-modifying antirheumatic drugs jak inhibitors covid-19 |
| url | https://rsp.mediar-press.net/rsp/article/view/3146 |
| work_keys_str_mv | AT aekarateev theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT eyupolishchuk theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT aspotapova theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT evmatyanova theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT assemashko theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT aobobkova theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT esfilatova theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT vnamirjanova theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT siglukhova theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT egzotkin theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT amlila theuseofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT aekarateev useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT eyupolishchuk useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT aspotapova useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT evmatyanova useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT assemashko useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT aobobkova useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT esfilatova useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT vnamirjanova useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT siglukhova useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT egzotkin useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients AT amlila useofbiologicaldiseasemodifyingantirheumaticdrugsandjanuskinaseinhibitorsinrheumatoidarthritisduringthecovid19coronavirusdiseasepandemicdatafromatelephonesurveyof254patients |